Mati Therapeutics

Mati Therapeutics is pioneering a novel drug delivery approach in ophthalmology with its Evolute® Punctal Plug Delivery System, a small, cosmetically invisible device inserted into the tear duct. This platform aims to solve the critical problem of poor adherence to topical eye drop regimens, a major issue in managing chronic diseases like glaucoma. The company is led by founders with extensive experience from major ophthalmic players like Allergan and Abbott. Mati is positioned to address a significant unmet need in a large global market of patients with vision impairment from treatable causes.

Evolute® Punctal Plug Delivery System: a small, non-invasive, sustained-release device inserted into the tear duct to automatically deliver medication to the eye over an extended period, eliminating the need for patient-administered eye drops.

The competitive landscape includes other sustained-release technologies like intracameral implants (e.g., Durysta) and injectable intravitreal implants, as well as other punctal plug delivery systems in development. Traditional pharmaceutical companies with branded glaucoma drops also represent competition, though Mati's technology aims to replace them by solving the adherence issue inherent to their products.